154 related articles for article (PubMed ID: 26179145)
1. Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.
Hu L; Lv QL; Guo Y; Cheng L; Wu NY; Qin CZ; Zhou HH
J Clin Pharmacol; 2016 Mar; 56(3):349-54. PubMed ID: 26179145
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene polymorphisms on the systemic toxicity to paclitaxel/carboplatin chemotherapy for treatment of gynecologic cancers.
de Castro CL; da Costa Junior LC; Lourenço LV; Seba KS; da Silva TSL; Vianna-Jorge R
Arch Gynecol Obstet; 2019 Aug; 300(2):395-407. PubMed ID: 31123858
[TBL] [Abstract][Full Text] [Related]
4. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
5. Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic.
Ishikawa M; Kawai M; Maeda T; Kagawa Y
Cancer Chemother Pharmacol; 2018 Feb; 81(2):399-411. PubMed ID: 29299638
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
Glaze S; Teitelbaum L; Chu P; Ghatage P; Nation J; Nelson G
J Obstet Gynaecol Can; 2013 Jan; 35(1):61-7. PubMed ID: 23343799
[TBL] [Abstract][Full Text] [Related]
8. Improved outcomes with dose-dense paclitaxel-based neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
Becker DA; Thomas ED; Gilbert AL; Boone JD; Straughn JM; Huh WK; Bevis KS; Leath CA; Alvarez RD
Gynecol Oncol; 2016 Jul; 142(1):25-29. PubMed ID: 27130405
[TBL] [Abstract][Full Text] [Related]
9. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
10. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer.
Lee CK; Gurney H; Brown C; Sorio R; Donadello N; Tulunay G; Meier W; Bacon M; Maenpaa J; Petru E; Reed N; Gebski V; Pujade-Lauraine E; Lord S; Simes RJ; Friedlander M
Br J Cancer; 2011 Jul; 105(3):360-5. PubMed ID: 21750553
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer.
Bouchard-Fortier G; Rosen B; Vyarvelska I; Pasetka M; Covens A; Gien LT; Kupets R; Pulman K; Ferguson SE; Vicus D
Gynecol Oncol; 2016 Jan; 140(1):36-41. PubMed ID: 26546964
[TBL] [Abstract][Full Text] [Related]
13. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
14. The trend of chemotherapy-induced peripheral neurotoxicity in ovarian cancer survivors and its impacts on daily life during and one year after treatment.
Jing Y; Lv HY; Feng SW
Eur J Gynaecol Oncol; 2016; 37(5):696-699. PubMed ID: 29787013
[TBL] [Abstract][Full Text] [Related]
15. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of paclitaxel and carboplatin with a biweekly schedule in patients with epithelial ovarian cancer: Gynecologic Cancer Network trial.
Yoneyama K; Konishi H; Yahata T; Fujita K; Aoki Y; Doi D; Matsushima T; Kodama S; Honma S; Kato H; Nakayama H; Kamoi S; Asakura H; Takeshita T; Tanaka K
J Nippon Med Sch; 2014; 81(1):28-34. PubMed ID: 24614392
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
18. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
19. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
20. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
